Drug Discovery Opinion

There is no single test that will diagnose Alzheimer’s disease (AD) and a diagnosis of possible or probable AD is currently based on neuropsychological tests together with advanced brain imaging techniques such as functional MRI or PET scans. Simple and reliable diagnostic tests for AD are much needed, and researchers at the University of Georgia have now shown that the levels of two antibodies in the blood correlate with the severity of AD symptoms and may provide just such a test. The team had previously shown that levels of anti-Aβ and anti-RAGE antibodies were significantly higher in AD patients than in healthy individuals and the latest study reveals a direct relationship between the severity of disease and the levels of the two antibodies. Much evidence points to a link between AD and elevated levels of β-amyloid (Aβ) peptides. Binding of Aβ to neuronal membrane receptors for advanced glycation end products (RAGE) is believed to trigger inflammation and contribute to the neurological damage characteristic of AD.

Although it could be years before a diagnostic test based on their work is available for clinical use, the researchers hope that it will, one day, provide a way of identifying people with early AD and those at risk of developing the disease. The study is published in full in The Journals of Gerontology.

Bookmark It

Hide Sites

Related posts:

1. Calpain Inhibitors in Models of Alzheimer’s Disease Calpains are calcium-activated cysteine proteases which, when abnormally activated, can initiate degradation of proteins essential for neuronal survival. A report...
2. New Role for APP in Alzheimer’s Disease Cleavage of amyloid precursor protein (APP) by β- and γ-secretases into neurotoxic β-amyloid peptides is believed to play a leading...
3. GPCR Target for Alzheimer’s Disease Available treatments for Alzheimer’s disease offer relatively small symptomatic benefits and more effective treatments are much needed. β-Amyloid has been...
4. Three New Kinase Targets for Alzheimer’s Disease Neurofibrillary tangles (NFT) are a hallmark of Alzheimer’s disease (AD) and correlate strongly with synaptic loss and severity of dementia....
5. Insulin Growth Factor Signalling in Alzheimer’s Disease Although family history and lifestyle choices play a role, ageing is recognised to be the largest single risk factor for...

Related posts brought to you by Yet Another Related Posts Plugin.

 Email This Post

This entry was posted on Monday, March 16th, 2009 at 8:52 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.